In a March 28 press release, RXi Pharmaceuticals Corp. (RXII:NASDAQ) announced the patent grant from the Japan Patent Office for RXI-109, which is in clinical trials for post-surgical hypertrophic scarring and for retinal scarring associated with age-related macular degeneration. The patent protection extends to 2031.
"This patent increases our ability to protect our novel CTGF (connective tissue growth factor)-targeting compounds, which are based on our proprietary self-delivering RNAi platform," stated the company's chief development officer, Pamela Pavco, in the press release. "The granting of this patent in Japan further strengthens RXi's intellectual property estate for future commercial and regional business development opportunities for RXI-109."
RXi's platform, called sd-rxRNA, consists of "self-delivering" RNAi compounds that can "achieve efficient spontaneous cellular uptake and potent, long-lasting intracellular activity," according to the company.
RXI-109 is currently in Phase 2 studies for post-surgical hypertrophic scarring, where preliminary results show "the use of RXI-109 after scar revision surgery had a visible, beneficial effect on the suppression of hypertrophic scarring, at three months following revision surgery," Pavco stated. Data from the trail is expected by Q4/17.
The compound has also proven "safe and well-tolerated in the eye" in an ongoing Phase 1/2 trial, according to Pavco. That trial is expected to read out in 2018, and while the primary endpoint is to ensure there are no safety issues, the company will also be monitoring the sizes of existing scars, which may give some indication of efficacy.
The company is also using its sd-rxRNA technology to enhance cancer immunotherapies. RXi exercised its option to acquire MirImmune, which had licensed RXiís sd-rxRNA technology to enhance its immunotherapeutic work, in February, formalizing a long-standing collaboration.
In a recent presentation at the American Association for Cancer Research's annual meeting, RXi illustrated the methodology and results of its platform in a preclinical study of sd-rxRNA-augmented immunotherapy in ovarian cancer. The company's conclusions stated the "sd-rxRNA is a powerful RNAi platform for the silencing of immune checkpoints in therapeutic cells," and that "[e]ffective simultaneous modulation of multiple immune checkpoints by sd-rxRNA provides a flexible tool for improving efficacy of cell-based immunotherapies."
In addition to its sd-rxRNA platform, RXi has a small molecule compound, Samcyprone, which is in Phase 2 for treatment of warts caused by human papillomavirus. Data from that trial is also expected by year-end.
Read what other experts are saying about:
Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She owns, or her family owns, shares of the following companies mentioned in this interview: None. She is, or members of her immediate household or family are, paid by the following companies mentioned in this article: None.
2) RXi Pharmaceuticals Corp. is a sponsor of Streetwise Reports. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.